Integrilin and Coagulation time abnormal - a phase IV clinical study of FDA data

Summary:

Coagulation time abnormal is reported as a side effect among people who take Integrilin (eptifibatide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Angiomax, and have Percutaneous coronary intervention.

The phase IV clinical study analyzes which people have Coagulation time abnormal when taking Integrilin. It is created by eHealthMe based on reports of 3,029 people who have side effects when taking Integrilin from the FDA, and is updated regularly.

What is Integrilin?

Integrilin has active ingredients of eptifibatide. eHealthMe is studying from 3,037 Integrilin users. Check the latest studies of Integrilin.

What is Coagulation time abnormal?

Coagulation time abnormal is found to be associated with 37 drugs and 117 conditions by eHealthMe. Check the latest studies of Coagulation time abnormal.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

3,029 people reported to have side effects when taking Integrilin.
Among them, 17 people (0.56%) have Coagulation time abnormal.

Could Integrilin cause Coagulation time abnormal?

Among these 17 people:

How long have people been on Integrilin when they have Coagulation time abnormal? *

What is the gender of people who have Coagulation time abnormal when taking Integrilin? *

female: 25 %
male: 75 %

What is the age of people who have Coagulation time abnormal when taking Integrilin? *

What are other drugs people take besides Integrilin? *

What are other side effects people have besides Coagulation time abnormal? *

Coronary Artery Thrombosis (clot formation in coronary artery): 9 people, 52.94%
Heart Attack: 5 people, 29.41%
Cardiac Arrest: 4 people, 23.53%
Catheter Thrombosis (blood clot at site): 3 people, 17.65%
Ventricular Fibrillation (abnormally irregular heart rhythm): 2 people, 11.76%
Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 11.76%
Coronary Artery Occlusion (complete obstruction of blood flow in a coronary artery): 2 people, 11.76%
Drug Ineffective: 2 people, 11.76%
Hypotension (abnormally low blood pressure): 2 people, 11.76%
Medical Device Complication: 2 people, 11.76%

What are the existing conditions these people have? *

Percutaneous Coronary Intervention: 13 people, 76.47%

* Approximation only. Some reports may have incomplete information.

Do you take Integrilin and have Coagulation time abnormal?

- Check whether Coagulation time abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Integrilin:

Integrilin (3,037 reports)

Browse all side effects of Integrilin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Coagulation time abnormal:

Coagulation time abnormal (37 drugs)

Browse all the conditions that are associated with Coagulation time abnormal:

Coagulation time abnormal (117 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eptifibatide (the active ingredients of Integrilin) and Integrilin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.